Incyte and AstraZeneca will expand their clinical collaboration and evaluate how Incyte’s apacadostat and AstraZeneca’s Imfinzi work in combination, compared with Imfinzi alone.
Apacadostat is Incyte’s investigational selective IDO1 enzyme inhibitor. Imfinzi is AstraZeneca’s human monoclonal antibody.
The collaboration allows the two companies to conduct a Phase 3 trial in patients with stage three non-small cell lung cancer whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy.
The Phase 3 trial, which will be co-funded by the two companies and will be conducted by AstraZeneca, is expected to begin enrolling patients in the first-half of 2018. This agreement builds on an existing clinical collaboration for epacadostat and Imfinzi, announced by both companies in May 2014.